Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cariprazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 11/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariprazine SCHEMBL184343 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL26301652 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL29395059 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL183803 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL29393456 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL183804 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL30574605 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL30225016 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL1774396 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL1775021 | 0.99 | DRD2 (0.98) | DRD2DRD3HTR1ADRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1994 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4744650-A1 | METHOD FOR PREPARING CARIPRAZINE MICROSPHERES, MICROSPHERES PREPARED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING MICROSPHERES | Aulbio Co., Ltd. (KR) | 2026-05-20 | — | — | EP | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4736842-A1 | IN SITU GEL FORMULATION AND PREPARATION METHOD THEREOF | ANXO Pharmaceutical Co., Ltd. (TW) | 2026-05-06 | — | — | EP | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4706641-A1 | A CAPSULE FORMULATION COMPRISING CARIPRAZINE HYDROCHLORIDE | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2026-03-11 | — | — | EP | claimed |
| US-20260060972-A1 | Quantitative Method of Determining a Mental Status Based on DRD1 and/or DRD5, and its Application Thereof | SHI XIANDONG (US) | 2026-03-05 | — | — | US | claimed |
| EP-2164572-A2 | CARBAMOYL-CYCLOHEXANES FOR TREATING ACUTE MANIA | Richter Gedeon NYRT (HU) | 2010-03-24 | — | — | EP | claimed |
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | RICHTER GEDEON NYRT. (HU) | 2010-01-21 | — | — | US | claimed |
| US-20090275597-A1 | METHODS OF TREATING CNS DISORDERS | FOREST LABORATORIES HOLDINGS LIMITED (BE) | 2009-11-05 | — | — | US | claimed |
| WO-2009020897-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-02-12 | — | — | WO | claimed |
| US-20090036468-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-02-05 | — | — | US | claimed |
| WO-2008142463-A2 | CARBAMOYL-CYCLOHEXANES FOR TREATING ACUTE MANIA | RICHTER GEDEON NYRT. (HU) | 2008-11-27 | — | — | WO | claimed |
| WO-2008142462-A1 | (THIO) -CARBAMOYL-CYCLOHEXANE DERIVATIVES AND METHOD FOR TREATING SCHIZOPHRENIA | RICHTER GEDEON NYRT. (HU) | 2008-11-27 | — | — | WO | claimed |
| US-20060229297-A1 | (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-10-12 | — | — | US | claimed |
| EP-1663996-A1 | (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2006-06-07 | — | — | EP | claimed |
| WO-2005012266-A1 | (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | DRD2 3354/4885DRD3 3367/4885HTR1A 2729/4885 |
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | PRLHR, SLC6A3, SLC18A2 | DRD2 30/4885DRD3 93/4885HTR1A 17/4885 |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | DRD2 186/4885DRD3 330/4885HTR1A 114/4885 |
| US-20090036468-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS | HTR5A, SLC6A3, HTR1A | DRD2 12/4885DRD3 54/4885HTR1A 3/4885 |
| US-20060229297-A1 | (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | DRD3, DRD2, TACR2 | DRD2 2/4885DRD3 1/4885HTR1A 172/4885 |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | DRD2 32/4885DRD3 113/4885HTR1A 34/4885 |
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | RPS6KA3, RPS6KA1, CDK9 | DRD2 2377/4885DRD3 1746/4885HTR1A 2852/4885 |
| US-20090275597-A1 | METHODS OF TREATING CNS DISORDERS | GRIN3A, GRIN2A, GRIN2B | DRD2 126/4885DRD3 156/4885HTR1A 176/4885 |
| US-20260060972-A1 | Quantitative Method of Determining a Mental Status Based on DRD1 and/or DRD5, and its Application Thereof | DRD2, DRD4, DRD5 | DRD2 1/4885DRD3 5/4885HTR1A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.